首页> 美国卫生研究院文献>Drug Design Development and Therapy >Biodegradable in situ gelling delivery systems containing pilocarpine as new antiglaucoma formulations: effect of a mercaptoacetic acid/N-isopropylacrylamide molar ratio
【2h】

Biodegradable in situ gelling delivery systems containing pilocarpine as new antiglaucoma formulations: effect of a mercaptoacetic acid/N-isopropylacrylamide molar ratio

机译:含有毛果芸香碱作为新抗青光眼制剂的可生物降解的原位凝胶递送系统:巯基乙酸/ N-异丙基丙烯酰胺摩尔比的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ocular drug delivery is one of the most commonly used treatment modalities in the management of glaucoma. We have recently proposed the use of gelatin and poly(N-isopropylacrylamide) (PNIPAAm) graft copolymers as biodegradable in situ forming delivery systems for the intracameral administration of antiglaucoma medications. In this study, we further investigated the influence of carrier characteristics on drug delivery performance. The carboxyl-terminated PNIPAAm samples with different molecular weights were synthesized by varying the molar ratio of mercaptoacetic acid (MAA)/N-isopropylacrylamide (NIPAAm) from 0.05 to 1.25, and were determined by end-group titration. The preparation of gelatin-g-PNIPAAm (GN) copolymers from these thermoresponsive polymers was achieved using carbodiimide chemistry. Our results showed that the carboxylic end-capped PNIPAAm of high molecular weight may lead to the lower thermal phase transition temperature and slower degradation rate of GN vehicles than its low molecular weight counterparts. With a decreasing MAA/NIPAAm molar ratio, the drug encapsulation efficiency of copolymers was increased due to fast temperature-triggered capture of pilocarpine nitrate. The degradation of the gelatin network could greatly affect the drug release profiles. All of the GN copolymeric carriers demonstrated good corneal endothelial cell and tissue compatibility. It is concluded that different types of GN-based delivery systems exhibit noticeably distinct intraocular pressure-lowering effect and miosis action, thereby reflecting the potential value of a MAA/NIPAAm molar ratio in the development of new antiglaucoma formulations.
机译:眼内给药是青光眼治疗中最常用的治疗方式之一。我们最近提出使用明胶和聚(N-异丙基丙烯酰胺)(PNIPAAm)接枝共聚物作为可生物降解的原位形成递送系统,用于抗青光眼药物的前房内给药。在这项研究中,我们进一步研究了载体特性对药物递送性能的影响。通过改变巯基乙酸(MAA)/ N-异丙基丙烯酰胺(NIPAAm)的摩尔比从0.05到1.25,合成具有不同分子量的羧基封端PNIPAAm样品,并通过端基滴定法进行测定。使用碳二亚胺化学法可从这些热响应性聚合物中制备明胶-g-PNIPAAm(GN)共聚物。我们的结果表明,与低分子量的同类物相比,高分子量的羧基封端的PNIPAAm可能导致较低的GN载体热相变温度和较慢的降解速度。随着MAA / NIPAAm摩尔比的降低,由于快速触发了硝酸毛果芸香碱的捕获,提高了共聚物的药物包封效率。明胶网络的降解会极大地影响药物释放曲线。所有GN共聚物载体均表现出良好的角膜内皮细胞和组织相容性。结论是,不同类型的基于GN的递送系统表现出明显不同的眼内降压作用和瞳孔缩小作用,从而反映出在开发新的抗青光眼制剂中MAA / NIPAAm摩尔比的潜在价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号